Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

Those who suffer myasthenia gravis experience muscle weakness that can affect the muscles we use to blink, smile and move our bodies. Researchers used a cutting-edge imaging technique to uncover new ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile ...

New topline data from the MINT trial (NCT04524273), which is investigating inebilizumab in patients with generalized myasthenia gravis who are acetylcholine receptor (AChR) antibody or muscle ...

There is no guarantee that they will become commercially available for the use(s) under investigation. * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need v of a ...

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est ...

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia gravis The ME&MGopenTM study highlights the potential ...

Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at month 4, which deepened through month 12 (6.0 ...

Descartes-08 represents a flagship advancement in Cartesian’s mission to transform the treatment landscape for autoimmune diseases, with this latest data reinforcing its potential as a safe and ...

The FDA is reviewing a request for approval of FcRn blocker nipocalimab in generalized myasthenia gravis (gMG). J&J is late to the party, with argenx and UCB already selling rival FcRn blockers ...